Strides Pharma riding high on performance posts impressive figures .Highlight of the performance as below from the Board Meeting

Q3FY20 Consolidated revenues at ₹7,353m demonstrating 28% YoY and 2% QoQ
growth
 Consolidated EBITDA at ₹1,851m , up 185% YoY and 23% QoQ
 Reported EBITDA margins at 25.2% , a new milestone for Strides
 The regulated markets continue their positive trajectory with industry leading PostR&D EBITDA margins
 US markets clocked $66m quarterly run-rate with ~90% front end driven revenues

Strides, listed on the BSE Limited and National Stock Exchange of India Limited , is a global pharmaceutical Company headquartered in Bangalore, India. The Company mainly operates in the regulated markets and has an “in Africa for Africa” strategy along with an institutional business to service donor-funded markets.

The Company’s global manufacturing sites are located in IndiaBangalore (two sites), Pondicherry, and Chennai, Singapore, Italy- Milan, Kenya- Nairobi and USFlorida. The Company focusses on “difficult to manufacture” products that are sold in over 100 countries.